Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer

touchEXPERT OPINIONS for touchONCOLOGY An oncologist, a nurse and a urologist share their insights on the risks and benefits of androgen deprivation therapy, the barriers to equitable care and how to improve treatment adherence for patients with prostate cancer.  The experts Dr Tanya Dorff, City of Hope Comprehensive Cancer Center, Duarte, CA, USA Ms Brenda Martone, Northwestern Medicine, Chicago, IL, USA Dr Stephen Freedland, Cedars-Sinai, Los Angeles, CA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Pfizer Inc. and is jointly provided by USF Health and touchIME. For further information visit: touchoncology.com